NOVARTIS logo.jpg
New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
May 04, 2022 03:00 ET | Novartis Pharma AG
With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for...
NOVARTIS logo.jpg
Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
April 27, 2022 06:00 ET | Novartis Pharma AG
RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with...
NOVARTIS logo.jpg
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
April 26, 2022 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core...
NOVARTIS logo.jpg
Novartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme
April 26, 2022 01:00 ET | Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires du T1 en hausse de +5% (tcc1, +1% USD) et résultat opérationnel core en progression de 9% (tcc, +3% USD) Innovative Medicines (IM):...
NOVARTIS logo.jpg
Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten
April 26, 2022 01:00 ET | Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im ersten Quartal um +5% (kWk1, +1% USD), das operative Kernergebnis wuchs um +9% (kWk, +3% USD) Innovative Medicines (IM) steigerte den Umsatz...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
April 22, 2022 09:27 ET | Novartis Pharma AG
Opinion based on Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with...
Sandoz
Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
April 14, 2022 01:15 ET | Novartis Pharma AG
 Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does...
NOVARTIS logo.jpg
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
April 05, 2022 20:29 ET | Novartis Pharma AG
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by...
NOVARTIS logo.jpg
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
April 05, 2022 01:15 ET | Novartis Pharma AG
Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration...
NOVARTIS logo.jpg
Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity
April 04, 2022 01:00 ET | Novartis Pharma AG
 Ad hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of...